Skip to main content
. 2020 Sep 16;13:1756284820954114. doi: 10.1177/1756284820954114

Figure 3.

Figure 3.

Results of the probabilistic sensitivity analysis.

Results of the probabilistic sensitivity analysis presented in a cost-effectiveness plane, and cost-effectiveness acceptability curve, separately for CAPOX (a, b) and FOLFOX (c, d).

CAPOX, capecitabine plus oxaliplatin; FOLFOX, fluorouracil, leucovorin and oxaliplatin; QALY, quality-adjusted life-years.